Nicole Hahn1, Kelsey E Palmer2, Shilpa Klocke3, Thomas Delate4. 1. Clinical Pharmacy Specialist in Neurology for Kaiser Permanente Colorado, a Clinical Instructor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora and Clinical Affiliate Faculty at Regis University School of Pharmacy in Denver (nicole.m.hahn@kp.org). 2. Clinical Pharmacy Specialist in the Anticoagulation and Anemia Service for Kaiser Permanente Colorado in Denver (kelsey.e.palmer@kp.org). 3. Clinical Pharmacy Specialist in Neurology for Kaiser Permanente Colorado, a Clinical Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora and Clinical Affiliate Faculty at Regis University School of Pharmacy in Denver (shilpa.klocke@kp.org). 4. Clinical Pharmacy Research Scientist in the Pharmacy Department for Kaiser Permanente Colorado and a Clinical Instructor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora (tom.delate@kp.org).
Abstract
INTRODUCTION: For patients with a less-active (fewer relapses or complete recovery from relapses, less radiologic burden of disease, or no or limited disease-related disability) relapsing form of multiple sclerosis (MS), interferon (IFN) beta-1b subcutaneous is similar in efficacy to IFN beta-1a intramuscular and subcutaneous. The purpose of this study was to assess the impact of patient interchange from an IFN beta-1a to IFN beta-1b. METHODS: This was a retrospective, pre-post study of adult patients with relapsing MS who underwent interchange from an IFN beta-1a to IFN beta-1b between April 15, 2014, and April 30, 2015. Health care financial and utilization outcomes between the 6 months before and after interchange were compared, and safety outcomes after interchange were assessed. RESULTS: A total of 36 primarily white, middle-age, and female patients underwent interchange. Monthly total health care and pharmacy expenditures decreased by approximately 40% and 44%, respectively, from pre-to-post interchange (p < 0.001). Health care utilization was unchanged (p < 0.05). Seven (43.8%) patients underwent interchange back to IFN beta-1a intramuscular. No patients underwent interchange back to IFN beta-1a subcutaneous. The most common adverse effect reported after interchange was injection-site reaction. CONCLUSION: Health care expenditures decreased and adverse effects were limited among patients with MS who underwent an interchange from an IFN beta-1a to IFN beta-1b. These findings suggest that a therapeutic interchange between IFNs for patients with less-active MS disease is well tolerated. Further research is needed to determine the impact of such an interchange on disease progression.
INTRODUCTION: For patients with a less-active (fewer relapses or complete recovery from relapses, less radiologic burden of disease, or no or limited disease-related disability) relapsing form of multiple sclerosis (MS), interferon (IFN) beta-1b subcutaneous is similar in efficacy to IFN beta-1a intramuscular and subcutaneous. The purpose of this study was to assess the impact of patient interchange from an IFN beta-1a to IFN beta-1b. METHODS: This was a retrospective, pre-post study of adult patients with relapsing MS who underwent interchange from an IFN beta-1a to IFN beta-1b between April 15, 2014, and April 30, 2015. Health care financial and utilization outcomes between the 6 months before and after interchange were compared, and safety outcomes after interchange were assessed. RESULTS: A total of 36 primarily white, middle-age, and female patients underwent interchange. Monthly total health care and pharmacy expenditures decreased by approximately 40% and 44%, respectively, from pre-to-post interchange (p < 0.001). Health care utilization was unchanged (p < 0.05). Seven (43.8%) patients underwent interchange back to IFN beta-1a intramuscular. No patients underwent interchange back to IFN beta-1a subcutaneous. The most common adverse effect reported after interchange was injection-site reaction. CONCLUSION: Health care expenditures decreased and adverse effects were limited among patients with MS who underwent an interchange from an IFN beta-1a to IFN beta-1b. These findings suggest that a therapeutic interchange between IFNs for patients with less-active MS disease is well tolerated. Further research is needed to determine the impact of such an interchange on disease progression.
Authors: Neil Scolding; David Barnes; Sarah Cader; Jeremy Chataway; Abhijit Chaudhuri; Alasdair Coles; Gavin Giovannoni; David Miller; Waqar Rashid; Klaus Schmierer; Abdullah Shehu; Eli Silber; Carolyn Young; John Zajicek Journal: Pract Neurol Date: 2015-06-22
Authors: H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers Journal: Brain Date: 2010-06-09 Impact factor: 13.501
Authors: Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag Journal: Lancet Neurol Date: 2008-09-11 Impact factor: 44.182
Authors: D Cadavid; L J Wolansky; J Skurnick; J Lincoln; J Cheriyan; K Szczepanowski; S S Kamin; A R Pachner; J Halper; S D Cook Journal: Neurology Date: 2009-03-11 Impact factor: 9.910
Authors: Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre Journal: Can J Neurol Sci Date: 2013-05 Impact factor: 2.104
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: Annette Langer-Gould; Stephen C Cheng; Bonnie H Li; Jessica B Smith; Michael H Kanter Journal: Ann Neurol Date: 2022-03-30 Impact factor: 11.274